Difference between revisions of "C1 inhibitor"
m |
|||
| (3 intermediate revisions by one other user not shown) | |||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| − | | align="center" colspan="2" bgcolor="#ffffff" | [[Image: | + | | align="center" colspan="2" bgcolor="#ffffff" | [[Image:C1inhibitor.JPG|200px|{{PAGENAME}}]] |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 23: | Line 23: | ||
|- | |- | ||
| Reactive glutamines | | Reactive glutamines | ||
| − | | Q453 | + | | [[TG2 reactive residues (C1 inhibitor)|Q453]] |
|- | |- | ||
| Reactive lysines | | Reactive lysines | ||
| Line 33: | Line 33: | ||
|- | |- | ||
| Structure | | Structure | ||
| − | | | + | | [http://www.pdb.org/pdb/explore.do?structureId=2OAY 2OAY] |
|- | |- | ||
| Surface accessibility | | Surface accessibility | ||
| Line 48: | Line 48: | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:28, 10 March 2015
| C1 inhibitor | |
|---|---|
| |
| Substrate peptide name | C1 inhibitor |
| Synonyms | C1 esterase inhibitor |
| Determination type | In vitro |
| Source | Homo sapiens |
| Subcellular localization | Extracellular; plasma |
| Swissprot ID | P05155 |
| Reactive glutamines | Q453 |
| Reactive lysines | - |
| Substrate sequence | VFEVQQPFLFV |
| Structure | 2OAY |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:10799541 |
| Notes | TG2 action does not influence the protein's function |
